Nautilus Biotechnology (NASDAQ:NAUT) Stock Bumped Up to “Strong-Buy” by Roth Capital

Nautilus Biotechnology (NASDAQ:NAUT) was upgraded by equities research analysts at Roth Capital to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks reports.

A number of other brokerages have also recently commented on NAUT. Weiss Ratings cut shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Leerink Partners started coverage on Nautilus Biotechnology in a research note on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Nautilus Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $3.83.

Nautilus Biotechnology Trading Up 23.4%

NAUT stock opened at $1.37 on Tuesday. Nautilus Biotechnology has a 12-month low of $0.80 and a 12-month high of $4.31. The business’s 50-day moving average is $1.02 and its 200 day moving average is $2.03. The stock has a market cap of $174.33 million, a price-to-earnings ratio of -3.04 and a beta of 0.87.

Nautilus Biotechnology (NASDAQ:NAUT) last released its earnings results on Monday, July 27th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.10 million.

Institutional Investors Weigh In On Nautilus Biotechnology

Several institutional investors have recently modified their holdings of NAUT. Squarepoint Ops LLC acquired a new position in shares of Nautilus Biotechnology during the 2nd quarter worth approximately $63,000. Corient Private Wealth LP increased its position in Nautilus Biotechnology by 43.6% during the second quarter. Corient Private Wealth LP now owns 164,788 shares of the company’s stock worth $308,000 after purchasing an additional 50,000 shares during the last quarter. TD Waterhouse Canada Inc. boosted its holdings in shares of Nautilus Biotechnology by 1,500.0% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock valued at $29,000 after purchasing an additional 15,000 shares during the last quarter. AXQ Capital LP acquired a new position in Nautilus Biotechnology in the second quarter valued at $64,000. Finally, Susquehanna International Group LLP increased its position in Nautilus Biotechnology by 1,710.9% during the 2nd quarter. Susquehanna International Group LLP now owns 890,949 shares of the company’s stock worth $1,666,000 after purchasing an additional 841,749 shares in the last quarter. Hedge funds and other institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods.

The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine.

Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington.